Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | GFER | P55789 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18436557 | 0.84 | ADRB1 (0.43) | MAPTGAAKDM4EALDH1A1KMT2A | |
| SCHEMBL24352269 | 0.83 | ALDH1A1 (0.46) | MAPTGAAKDM4EALDH1A1KMT2A | |
| SCHEMBL31276657 | 0.83 | AKR1C3 (0.41) | MAPTKDM4EALDH1A1KMT2AHTT | |
| SCHEMBL18436319 | 0.82 | LMNA (0.52) | MAPTALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL21396334 | 0.82 | BACE1 (0.37) | MAPTGAAKDM4EALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL21384900 | 0.82 | NOS3 (0.36) | GAAKMT2AL3MBTL1NPC1RAB9A | |
| SCHEMBL21388686 | 0.81 | PIK3CA (0.38) | MAPTGAAKDM4EALDH1A1KMT2A | |
| SCHEMBL19012685 | 0.80 | MAPT (0.45) | MAPTALDH1A1KMT2AHTTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL21378575 | 0.80 | PIK3CA (0.37) | MAPTGAAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL22650906 | 0.80 | MTOR (0.55) | BACE1PIK3CAMTORPRKDCPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20040116417-A1 | Thiohydantoins and use thereof for treating diabetes | LABORATOIRES FOURNIER SA (FR) | 2004-06-17 | — | — | US | disclosed |
| EP-1373219-A1 | THIOHYDANTOINS AND USE THEREOF FOR TREATING DIABETES | LABORATOIRES FOURNIER S.A. (FR) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002081453-A1 | THIOHYDANTOINS AND USE THEREOF FOR TREATING DIABETES | LABORATOIRES FOURNIER SA (FR) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAPT 501/4885GFER 4102/4885GAA 940/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAPT 470/4885GFER 3828/4885GAA 742/4885 |
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | TYMP, DPYD, TYMS | MAPT 3729/4885GFER 4277/4885GAA 921/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MAPT 438/4885GFER 3792/4885GAA 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.